On June 13, 2023 Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, reported that the Company will present the latest developments on GalAhead, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at three international industry conferences taking place in June: the Precision in Drug Discovery & Preclinical Summit, RNA Therapeutics USA, and 19th Drug Discovery Nexus (Press release, Sirnaomics, JUN 13, 2023, View Source [SID1234632676]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company’s first GalAhead-based RNAi drug candidate, STP122G, has started a Phase I clinical trial in May 2023. The start of the trial indicates that Sirnaomics’ proprietary GalNAc RNAi platform technology, GalAhead, has the potential to help patients with high unmet needs in the areas of hematologic, cardiometabolic, immunologic and rare disorders.
Precision in Drug Discovery & Preclinical Summit Oral Presentation Details
Presentation Title: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes
Presenter: Dmitry Samarsky, PhD, Sirnaomics Chief Technology Officer
Time/Date: 2:55 pm-3:20 pm ET on Tuesday, Jun 13, 2023
Location: Revere Hotel, Boston, USA
RNA Therapeutics USA Oral Presentation Details
Presentation Title: GalAhead: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple Genes
Presenter: Jim Weterings, PhD, Sirnaomics Senior Director of Technology Innovation
Time/Date: 3:10 pm-3:50 pm ET on Thursday, June 15, 2023
Location: Horton Grand Hotel; San Diego, USA
19th Drug Discovery Nexus Oral Presentation Details
Presentation Title: GalAhead: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes
Presenter: Jack Wei, PhD, Sirnaomics Senior Director of Drug Discovery
Time/Date: 3:15 pm -3:40 pm ET on Friday, June 16, 2023
Location: Holiday Inn Express – Arena Towers; Amsterdam, Netherlands
About the GalAhead Technology
The GalAhead is a proprietary technology platform for RNAi therapeutics, developed by Sirnaomics. The GalAhead platform relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA (miniaturized RNAi triggers) and muRNA (multi-unit RNAi triggers). mxRNAs are comprised of single ~30 nt long oligonucleotides to downregulate individual genes, while muRNA molecules are comprised of multiple oligonucleotides to silence two or more targets simultaneously. The targeted delivery technology has demonstrated specific liver hepatocyte targeting via a cell surface receptor ASGPR.